MRI鉴别肝细胞癌患者恶性与良性门静脉血栓:减影增强成像的价值
回顾性分析6年间39例肝细胞癌合并门静脉血栓患者的腹部MRI,由两名专科放射科医师盲法评估增强前后及减影各期信号强度、DWI定性参数和门静脉增宽。增强百分比在非减影和减影动脉期、门静脉期、延迟期均获高AUC,良恶性血栓间门静脉增宽差异有统计学意义,DWI定性参数均未达统计学显著。结论为增强及减影MRI可可靠区分良恶性门静脉血栓。
要点
- 增强百分比在减影与非减影的动脉期、门静脉期、延迟期均可高AUC区分良恶性门静脉血栓。
- 门静脉增宽在良性与恶性血栓间差异有统计学意义。
- DWI定性参数在两名阅片者中均未达统计学显著。
核心结论
- 增强及减影MRI利用减影或非减影图像、在动脉期、门静脉期或延迟期均可可靠区分肝细胞癌患者的恶性与良性门静脉血栓。
研究设计与样本
- 回顾性研究,检索截至2016年2月的6年间腹部MRI报告中同时提示肝细胞癌和门静脉血栓的病例,共识别39例门静脉血栓患者。
- 血栓良恶性依据病理数据或系列影像生长标准判定。
- 由两名专科放射科医师在不知诊断和病历的情况下进行图像评估。
关键影像表现/征象
- 记录门静脉血栓及门静脉感兴趣区在增强前、动态增强后各期(减影与非减影)的信号强度。
- 评估DWI定性参数及门静脉增宽的有无。
诊断标准与关键数值
- 增强百分比在两名阅片者的非减影各期AUC分别为:动脉期0.95/0.98、门静脉期0.97/0.97、延迟期0.96/0.99。
- 增强百分比在两名阅片者的减影各期AUC分别为:动脉期0.91/0.96、门静脉期0.94/0.99、延迟期0.96/0.97。
- 门静脉增宽在良性与恶性血栓间差异有统计学意义,两名阅片者p值分别为<0.001和0.006。
- DWI定性参数在两名阅片者中均未达统计学显著。
临床应用与阅片要点
- 阅片时可利用增强百分比在减影或非减影图像的动脉期、门静脉期或延迟期评估门静脉血栓性质。
- 门静脉增宽的存在与否有助于区分良恶性血栓。
- DWI定性参数在本研究中未能提供有统计学意义的鉴别价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate MR imaging parameters including quantitative multiphasic post-contrast enhancement with subtraction and qualitative diffusion weighted imaging (DWI) in differentiating benign versus malignant portal venous thrombosis (PVT) in patients with hepatocellular carcinoma (HCC).
METHOD: Radiology reports over a 6-year period ending February 2016 were searched for key words indicating presence of both HCC and PVT on abdominal MRI. 39 patients were identified with PVT characterized as benign or malignant based on pathologic data or serial imaging growth criteria. Image review was performed by two subspecialized radiologists blinded to the diagnosis and medical chart. Signal intensity for regions of interest were recorded within the portal vein thrombus as well as the portal vein on pre-contrast and dynamic post-contrast phases without and with subtraction. Qualitative parameters for DWI and presence of PV expansion were also evaluated.
RESULTS: Percent enhancement generated high area under the curve (AUC) for both readers on all non-subtraction phases: arterial (0.95/0.98), portal venous (0.97/0.97) and delayed phase (0.96/0.99) and subtraction phases: arterial (0.91/0.96), portal venous (0.94/0.99) and delayed phases (0.96/0.97). Statistically significant differences were observed between benign and malignant PVT for both readers for PV expansion (p= <0.001/0.006). No qualitative DWI parameter reached statistical significance for both readers.
CONCLUSIONS: Post-contrast and subtraction MRI can reliably distinguish malignant from benign PVT in patients with HCC using subtracted or non-subtracted images and at arterial, portal venous, or delayed phase timing.
引用
- Gawande R, Jalaeian H, Niendorf E, et al. MRI in differentiating malignant versus benign portal vein thrombosis in patients with hepatocellular carcinoma: Value of post contrast imaging with subtraction. Eur J Radiol. 2019. PMID: 31439264. doi:10.1016/j.ejrad.2019.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。